The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Incyte; Infinity Pharmaceuticals; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Novartis; Pfizer; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
 
Frédéric Pouliot
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen; Progenics; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma; Bayer; Sanofi
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Viktor Stus
No Relationships to Disclose
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen
 
Rustem Gafanov
Honoraria - Janssen, Astellas, Bayer, Sanofi, MSD, BMS, PFIZER
Consulting or Advisory Role - Janssen, Astellas, Bayer, Sanofi, MSD, BMS, PFIZER
Speakers' Bureau - Janssen, Astellas, Bayer, Sanofi, MSD, BMS, PFIZER
 
Dmitry Nosov
Consulting or Advisory Role - Bayer; Pfizer
 
Boris Alekseev
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; ICON Clinical Research; Janssen; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Maurice Markus
No Relationships to Disclose
 
Sophie Tartas
No Relationships to Disclose
 
Anna Kryzhanivska
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Cezary Szczylik
No Relationships to Disclose
 
Jianxin Lin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
L. Rhoda Molife
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pneuma Respiratory; Pyxis; Surface Oncology; Third Rock Ventures; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Brian I. Rini
Leadership - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer